IIBR > Covid19 > Collaborations

Collaborations

Scientific publications

Antibacterial and Antiviral Surgical Masks
A collaboration between IIBR, Hadassa Medical Center and Tera Novel yielded a proprietary spray, containing minute quantities of an antibacterial and antiviral additive, developed in IIBR. Surgical masks sprayed externally were found to have strong and fast antibacterial activity for as long as 6 months (on-going). The additive toxicity was tested in a rigorous animal test, and a No Effect Dose was determined. The masks were labeled safe for skin irritation in yet another animal test. Moreover, the active mask does not emit any chemicals (gases or particles) to the wearer and conforms to the European standard for breathability. The active mask has been approved for use and is currently in mass production.
Developing a rapid, sensitive and specific detection of SARS Cov-2 carries
A unique collaboration between IIBR, the Weizmann Inst and IDEA Biomedical is set to develop a rapid detection of SARS-Cov-2 viruses in carriers’ clinical samples without compromising on sensitivity and accuracy. The technology is based on IDEA automatic microscopic platform the “HERMES” combined with the unique labeled antibodies developed at IIBR. Together we aim to achieve a rapid detection system, with a capacity of hundred samples per minutes. Such rapid and high throughput detection system will be crucial to enable economic and social life throughout the pandemic.
Our goal is to establish a working prototype by the end of 2020.
Covid19 drug development based on siRNA for treating Corona patient
IIBR and Sirvir, a subsidiary company of Aposense, had recently started collaborative Research and Development Project with goal of accelerating development of a genetic therapy for the pandemic of Corona virus COVID-19.
The collaborative research study is focused on Aposense’s proprietary gene delivery platform, Molecular Nano-Motors attached to siRNa that was licensed to SirVir. IIBR unique facility and staff will perform the toxicity and efficacy studies of such molecular systems, single and combination, by using In-Vitro model.
So far we have discovered several leading systems, which will be transfer to further studies on different biologicals models.
New COVID-19 proteins were identified and might serve as new tools in diagnostic, prevention or treatment for COVID-19
A research collaboration between the Israel Institute for Biological Research, in Ness Ziona and the Weizmann Institute of Science, Israel uncovered the coding capacity of the SARS CoV-2 virus. The researchers applied an innovative method of tracking translating ribosomes on their RNA template and converting the data into a translational-map of all the proteins being translated in the infected cells. Using this innovative method, resulted in the identification of 23 new short protein (peptide) sequences in the SARS-CoV-2 genome that can contribute in a regulatory function, but four were full-fledged proteins and might serve as new tools in diagnostic, prevention or treatment of COVID-19.

Published: Nature 9 September 2020
The Israel Institute for Biological Research and the Weizmann Institute of Science Have Signed a Memorandum of Understanding to Collaborate in the Fight against Coronavirus
The Israel Institute for Biological Research and the Weizmann Institute of Science will join efforts in advancing research designed to develop ways to combat the coronavirus. A Memorandum of Understanding (MoU) between the two Institutes on this matter has been signed in recent days.
IIBR, TLS and AOUC have signed a memorandum of understanding in the fight against SARS-Cov-2
The collaboration aims to assess the conditions for developing a project to isolate new neutralizing monoclonal antibodies directed at SARS-Cov-2.
Collaboration between IIBR and Shaarey Zedek Medical Center explores a new method for detecting corona's markers through human breath analysis
Hundreds of volatile chemical compounds are exhaled in breath. In order to find markers specific for Corona, they need to be detected, identified and mapped. IIBR has developed unique methods for sensitive analysis and comprehensive data processing that are used in order to reliably identify these markers.
Dyadic and The Israel Institute for Biological Research (IIBR) Expand Collaboration to Combat Emerging Diseases
IIBR will explore the potential of Dyadic's industrially proven C1 gene expression platform to express gene sequences and targets developed by IIBR into both an rVaccine candidate and monoclonal antibodies (mAbs) that may help combat the outbreak of the COVID-19 virus (Coronavirus).

Collaborations

Antibacterial and Antiviral Surgical Masks

Developing a rapid, sensitive and specific detection of SARS Cov-2 carries

Covid19 drug development based on siRNA for treating Corona patient

New COVID-19 proteins were identified and might serve as new tools in diagnostic, prevention or treatment for COVID-19

The Israel Institute for Biological Research and the Weizmann Institute of Science Have Signed a Memorandum of Understanding to Collaborate in the Fight against Coronavirus

IIBR, TLS and AOUC have signed a memorandum of understanding in the fight against SARS-Cov-2

Collaboration between IIBR and Shaarey Zedek Medical Center explores a new method for detecting corona's markers through human breath analysis

Dyadic and The Israel Institute for Biological Research (IIBR) Expand Collaboration to Combat Emerging Diseases